Could a common heart drug fight staph infections too?

NCT ID NCT06650488

Recruiting now Disease control Sponsor: Todd C. Lee MD MPH FIDSA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether switching from aspirin to clopidogrel (another blood thinner) can reduce heart complications in people with a serious staph bloodstream infection. About 300 adults already taking aspirin for heart disease will be randomly assigned to stay on aspirin or switch to clopidogrel. The goal is to see if clopidogrel, which may also fight staph bacteria, leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clopidogrel
What this could lead to: If it works, this could point toward a better way to prevent heart complications in people with serious staph infections.
What could go wrong: This is a small, early-phase study (Phase 4) with only 300 participants. The drug may not work better than aspirin and could cause bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial endocarditis staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION STAPHYLOCOCCUS AUREUS ENDOCARDITIS STAPHYLOCOCCUS AUREUS SEPTICEMIA

Contacts and locations

Locations

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITING

Montreal, Quebec, H4A3S1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.